Results 281 to 290 of about 160,832 (337)

Targeting ARPC1B ⁺ Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment. [PDF]

Cell Prolif
Wu Y, Zhang J, Zhu W, Zhu X, Liu Y, Wang X, Zhao T, Zhang C, Zhang Z, Shi W, Shi R, Zhou Z, Xu S.   +12 more
europepmc   +1 more source

Advances in Tumor‐Derived Exosomal Non‐Coding RNAs Regulating M2 Macrophage Polarization: Molecular Mechanisms and Signaling Pathway

Cancer Medicine, Volume 14, Issue 23, December 2025.
ABSTRACT Background Cancer persists as a leading cause of global mortality, largely due to the immunosuppressive tumor microenvironment (TME) that facilitates tumor progression and therapy resistance. M2 macrophages dominate this immunosuppressive landscape, and emerging evidence highlights tumor‐derived exosomes (TEXs) as critical mediators of ...
Yifan Bian, Jilei Li, Jiarui Cao, Sizhe Wang, Chunzheng Ma   +4 more
wiley   +1 more source

JAVEMACS-D: claims database analysis of avelumab maintenance therapy for advanced urothelial carcinoma in Japan. [PDF]

Sci Rep
Kobayashi T, Kitamura H, Furukawa Y, Shono M, Ito T, Kikuchi E.   +5 more
europepmc   +1 more source

A meta-analysis of Pemetrexed plus Platinum Chemotherapy versus Gemcitabine plus Platinum Chemotherapy for Advanced Non-small Cell Lung Cancer

, 2011
Jin Jiang, Lun Li, Xiaojing WANG, Jinhui Tian, Quan WANG, Qiao Lin   +5 more
openalex   +1 more source

Predicting Benefit of Neoadjuvant Chemotherapy and Elective Nodal Irradiation in Pancreatic Adenocarcinoma: A Supervised Machine Learning Approach

Cancer Medicine, Volume 14, Issue 23, December 2025.
ABSTRACT Background The relative benefit of neoadjuvant therapies remains controversial for patients with (borderline) resectable pancreatic ductal adenocarcinoma (PDAC). The purpose of this study was to create a model to predict response to multiagent neoadjuvant chemotherapy (NAC) followed by radiotherapy with elective nodal irradiation (ENI ...
Garrett K. Harada, Jino Park, Nicholas Peterson, Akul Munjal, David Imagawa, Zeljka Jutric, Farshid Dayyani, Jennifer Valerin, David S. Hong, Steven N. Seyedin   +9 more
wiley   +1 more source

Second-Line Treatment in cholangiocarcinoma - Current State of the Art and Future Perspectives. [PDF]

Curr Treat Options Oncol
Siwek M, Chmiel P, Grabowska H, Grąt M, Kraj L.   +4 more
europepmc   +1 more source

Consensus and controversy in advanced urologic cancers: Insights from the Advanced Urologic Cancer Consensus Conference (AUC3) 2025

CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
Albert Jang, Yousef Zakharia, Pedro C. Barata   +2 more
wiley   +1 more source

Adjuvant treatment preferences in high-risk upper tract urothelial carcinoma: the perspective of Portuguese medical oncologists. [PDF]

Oncologist
Vilhais G, Fontes-Sousa M.
europepmc   +1 more source

Impact of <i>SERPINA3</i> on the Prognostic Role of KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients Receiving Gemcitabine-Based Treatment: A Cross-Sectional Study. [PDF]

Health Sci Rep
He X, Ren L, Dong S, Liu W.
europepmc   +1 more source

Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers. [PDF]

Liver Int
Rimini M, Fornaro L, Ikeda M, Abidoye O, Lucchetti J, Antonuzzo L, Kim JW, Nichetti F, Saborowski A, Pressiani T, Vivaldi C, Rapposelli IG, Peeters F, Braconi C, Pinato DJ, Tamburini E, Pircher C, Tamberi S, Castet F, Verrico M, Parisi A, Couto N, Chon HJ, Martirena A, Lamarca A, Landriscina M, Fimkelmeier F, Oneda E, Avallone A, Dell'Aquila E, Perkhofer L, Kim IH, Pinto CMS, Garajova I, Kang B, Corallo S, Fenocchio E, Farinea G, Pastorino A, Diana A, Changhoon Y, Schirripa M, Rodriquenz MG, Scartozzi M, Zumstein L, Ghidini M, Prager GW, Aprile G, Spinelli GP, Yung-Yeh S, Chan S, Warmington E, Lancianese A, Bekaii-Saab T, Lavacchi D, Kang M, Lonardi S, Vogel A, Prete AA, Bozzarelli S, Salani F, Persano M, Masi G, Balsano R, Niger M, Camera S, Passeri L, Ferrara M, Satake T, Rimassa L, Casadei-Gardini A.   +70 more
europepmc   +1 more source